Disclosed are radiomics and artificial-intelligence-based methods for predicting clinical cardiac assessment of FDG PET-CT scans. Certain embodiments use a computational method to extract features from one or more cardiac portions of diagnostic scans (e.g., FDG PET-CT scans). In certain embodiments, the method can use extracted features to predict cardiotoxicity for physician evaluation. In certain embodiments, the method can use the extracted features to predict for cardiac clinical complications. In certain embodiments, the method can enable early cardiac toxicity prediction for cancer patients using standard-of-care FDG PET-CT imaging. In certain embodiments, the method can provide a cardiac management decision support tool using standard-of-care FDG PET-CT imaging. In certain embodiments, the method can enable the incorporation of the extracted features in radiation treatment planning (e.g., for patients whose management involves radiation) using standard-of-care FDG PET-CT imaging.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
A method and system are disclosed based on artificial intelligence (AI) and machine learning (ML) to predict the radiation dose distribution and normal tissue doses directly from diagnostic imaging. More specifically, the invention uses features that more robustly enable the prediction of radiation dose distributions and normal tissue doses directly from diagnostic imaging, based on the use of AI and ML. One feature is the use of an expanded training set of diagnostic images of prior patients with known outcomes to train the AI/ML system. The training data can include, for example, prior scan data, prior delineation data, and radiation dose distribution of the patents associated with the prior scans and delineations. This provides a robust dosing distribution that can identify a desired radiation dose distribution earlier in the treatment of a patient.
The present invention relates, in part, to an oil-in-water emulsion comprising an emulsifying agent, an aqueous phase, an oil phase comprising squalene, and a monophosphoryl lipid adjuvant (MPLA), and methods of preparing and using the same. The present invention further relates to a vaccine composition comprising the emulsion of the present invention and an antigen and/or antigenic composition, and methods using the same.
A computer-implemented method is provided herein. One aspect of the invention provides a computer-implemented method including: (a) displaying a marker at a location on a display screen; (b) repositioning the marker in different locations across the display screen; (c) receiving, from a user input mechanism, user input; (d) determining a given location of the marker when the user input is received; and (e) determining from the received input, that a user views double vision of the marker at the given location.
A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
5.
AGONIST FUSION PROTEIN FOR CD40 AND OX40 AND USES THEREOF
Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
A sanitation system includes a sink, a sanitation material dispenser for dispensing material such as soap, and a dryer dispensing dryer material such as paper towels or providing heated air, wherein an electronic device may is in communication with one or more of these items, and a sanitation module operates on the sanitation system, where the sanitation module times a sanitation activity for the sanitation system, such as hand washing, where content is displayed on the electronic device, and the content serves to engage or distract the user, where the electronic device identifies the individual user and customizes the content, the sanitation module times the sanitation procedure and accordingly promotes a minimum time spent on the sanitation activity, and where the sanitation system may also be used to monitor the sanitation material or the dryer material and automatically order new material when the material is low.
A61L 2/28 - Devices for testing the effectiveness or completeness of sterilisation, e.g. indicators which change colour
A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
G08B 21/24 - Reminder alarms, e.g. anti-loss alarms
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
8.
SYSTEMS, DEVICES, AND METHODS FOR IMPLEMENTING COMPUTERIZED AMSLER GRID FOR EVALUATION OF VISUAL DISTURBANCES
A computer-implemented method is provided herein. One aspect of the method provides a computer-implemented method including: displaying a neuro-ophthalmic examination pattern comprising a plurality of segments, wherein each of the plurality of segments is displayed at a time offset and at a discrete location of a display screen compared to other segments of the plurality of segments; receiving user input during a time period which a given segment of the plurality of segments is displayed on the display screen; and generating a neuro-ophthalmic examination report based on the displaying the neuro-ophthalmic examination pattern and the received user input.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
9.
SYSTEMS AND METHODS FOR GENERATING NEURO-OPHTHALMIC EXAMINATIONS
A computer-implemented method is provided herein. One aspect of the invention provides a computer-implemented method including: (a) receiving a set of neuro-ophthalmic examination results for a patient; (b) identifying, from the set of neuro-ophthalmic examination results, a set of patient characteristics; and (c) adjusting one or more parameters of subsequent electronic neuro-ophthalmic examinations based on the set of patient characteristics.
A61B 3/18 - Arrangement of plural eye-testing or -examining apparatus
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
10.
A THERAPEUTIC AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS
The present disclosure provides a recombinant vector from an attenuated rabies virus comprising a nucleotide sequence encoding at least one CCHFV glycoprotein and at least one mucin like domain. The disclosure further provides a method for conditioning an immune response with said recombinant virus vector incorporated in said virus virion.
An apparatus comprises a processor and memory that stores instructions to cause the processor to receive user data that includes images of a body and organ. The processor is further caused to generate, via computed tomography imaging, a first image map and a second image map based on the user data. The processor is further caused to analyze, via spatial normalization of each image, the first image map and the second image map to determine strength of correlation of each tissue point of each image. The processor is further caused to execute a trained machine-learning model to generate a dose distribution image map using the first image map and the second image map as inputs. The processor is further caused to predict a change in a patient reported outcome for a user associated with the user data based on the dose distribution image map.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G06T 7/32 - Determination of transform parameters for the alignment of images, i.e. image registration using correlation-based methods
12.
APPAREL SYSTEMS AND METHODS FOR APPLYING TOPICAL TREATMENTS
An apparel system for applying topical treatments includes an article of apparel configured to cover and interface with a skin surface of a human body, the article of apparel including an oleophobic and moisture wicking layer. A method for applying a topical treatment is also disclosed.
A61K 9/00 - Medicinal preparations characterised by special physical form
B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
B32B 27/12 - Layered products essentially comprising synthetic resin next to a fibrous or filamentary layer
13.
INHIBITORS OF CIB1 INTERACTIONS AND METHODS OF USE
Provided herein are CIB1 (calcium and integrin binding 1) inhibitors and methods of use. The compounds are useful in treating, ameliorating, and/or preventing thrombotic conditions, disease, and disorders. The compounds are also useful in treating, ameliorating, and/or preventing cancer, neurodegenerative diseases, immune system diseases, and inflammation.
C07D 207/44 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
The present disclosure relates, in part, to compositions and methods for the at least partial removal of histamine from a fermented liquid. In one aspect, composition of the present disclosure comprises a histamine binding domain conjugated to a solid support via a cross-linker. In certain embodiments, the histamine binding domain comprises an aptamer. In certain embodiments, the histamine binding domain comprises an anti-histamine antibody.
C12H 1/056 - Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages combined with removal of precipitate or added materials, e.g. adsorption material with the aid of ion-exchange material or inert clarification material, e.g. adsorption material with the aid of organic material with the aid of polymers
15.
SYSTEMS, DEVICES, AND ASSOCIATED METHODS FOR THERAPEUTIC EUS ANCHOR
An endoscopic ultrasound (EUS) anchoring system is provided. The EUS anchoring system includes a needle sheath defining a sheath lumen. The EUS anchoring system also includes an endoscopic cannula translatable within the sheath lumen and defining a cannula lumen. The EUS anchoring system also includes an anchor translatable within the cannula lumen and egressable from a distal end of the endoscopic cannula. The EUS anchoring system also includes a wire suture translatable through the cannula lumen having a distal end coupled to a middle portion of the anchor. The EUS anchoring system also includes a cinch mechanism translatable within the sheath lumen and configured to: (a) cut the wire suture; and (b) couple a proximal end of the a cut wire suture still coupled to the anchor with a cinch.
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
The present disclosure relates, in part, to isolated nucleic acids encoding a recombinant virus comprising subolesin (SUB), or a portion thereof, and recombinant viruses and/or vectors comprising the same. The present disclosure further relates to vaccines comprising the isolated nucleic acids, recombinant viruses, and/or vectors of the present disclosure, and methods of use thereof.
A portable toilet transfer device comprises a clip configured to engage a toilet bowl, including a first end and a second end opposite the first end, comprising an interior side portion including a proximal end, a distal end, and an interior engagement member positioned at the distal end, an exterior side portion including a proximal end, a distal end, and an exterior engagement member positioned at the distal end, and a central portion connected to the proximal end of the interior side portion and the proximal end of the exterior side portion, and a handle connected to the clip. Methods of manufacture and use are also disclosed.
Described herein is a composition for treating, preventing, and/or ameliorating melanoma in a subject in need thereof. The composition includes in certain embodiments a MEK inhibitor and a PDPK1 inhibitor. The composition includes in certain embodiments a MEK inhibitor and a Pl3K inhibitor. Further described herein is a method of treating, preventing, and/or ameliorating melanoma in a subject in need thereof. The method includes in certain embodiments administering to the subject an effective amount of a composition including a MEK inhibitor and a PDPK1 inhibitor. The method includes in certain embodiments administering to the subject an effective amount of a composition including a MEK inhibitor and a Pl3K inhibitor.
The Trustees of the University of Pennsylvania (USA)
Thomas Jefferson University (USA)
Inventor
Cullen, Daniel Kacy
Harris, James P.
Wolf, John A.
Chen, Han-Chiao Isaac
Smith, Douglas H.
Serruya, Mijail
Abstract
In one aspect, the invention comprises an implantable living electrode comprising a substantially cylindrical extracellular matrix core; one or more neurons implanted along or within the substantially cylindrical extracellular matrix core, the one or more neurons including one or more optogenetic or magnetogenetic neurons proximal to a first end of the implantable living electrode.
A method of a sampling scheme for magnetic resonance diffusion metal artifact correction (DMAC) imaging includes identifying a region of interest of a body part of a human, the method further includes generating a plurality of readout trains using a plurality of radiofrequency pulses to excite the region of interest and produce a plurality of magnetic resonance imaging (MRI) signals. Each radiofrequency pulse from the plurality of radiofrequency pulses is configured to traverse along the same readout encoding (RE) direction in parallel. The method further includes applying a plurality of diffusion encoding parameters on the plurality of MRI signals. The method further includes generating, based on the plurality of diffusion encoding parameters, a reconstructed image of the region of interest that includes a reduced field of view (rFOV) along the phase encoding (PE) direction. The reconstructed image includes a high resolution and distortion reduced image of the region of interest.
A system for breast cancer detection using co-localized ultrasound-mammography is disclosed. The system includes an examination box having a cavity connected to a side opening. A compression plate is connected to an actuator, the actuator configured to advance a surface of the compression plate towards a breast positioned within the cavity from the side opening to compress and stabilize the breast. An x-ray device is configured to generate at least one mammography image. An ultrasound probe is configured to generate at least one ultrasound image. A controller is operably connected to the x-ray device and ultrasound probe, the controller configured generate an image based on co-localization of the at least one mammography image and at the least one ultrasound image. A method of performing breast cancer detection and methods of breast imaging are also disclosed.
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
24.
DNA-DEPENDENT SYNTHESIS OF RNA BY DNA POLYMERASE THETA VARIANTS
Synthetic RNA composed of canonical and modified ribonucleotides is highly effective for RNA antisense therapeutics, RNA based genome engineering applications and RNA based vaccines. Yet, synthesis of sequence-specific synthetic RNA using phosphoramidite chemistry is highly inefficient and expensive, especially for relatively long (>95 nt) RNA with chemical modifications. The present invention relates to enzymatic DNA-dependent synthesis of sequence-specific synthetic RNA with and without chemical modifications using A-family DNA polymerase variants and the use of such chemically modified RNA for applications such as RNA-based genome engineering and therapeutics.
The invention relates in one aspect to compounds, pharmaceutical compositions thereof, and methods using the same for selectively activating either all or a single isoform of Akt. Isoform selective-targeting is necessary for avoiding pathologies driven by concomitantly activated Akt1, Akt2 and/or Akt3.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
The present invention relates to the compositions comprising CAR cells, such as CAR-T cells, which target cell surface proteins. In certain compositions, the CAR cells target cell surface proteins associated with senescence. Accordingly, the invention also provides methods of administering said compositions for reducing the number senescent cells. These compositions and methods are of use in treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
27.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
In one aspect, the invention relates to a composition form preserving mouse-sperm, wherein the composition comprises raffinose, skim milk, monothiglycerol (MTG), and l-glutamine to reduce the oxidative damage during sperm freezing and thawing. The presently claimed composition comprising MTG and l-glutamine produced a synergistic impact on sperm thawing and IVF rate, which reduced incidence of infertility and increased the IVF success rate.
The present disclosure relates to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to treating or ameliorate nonalcoholic fatty liver disease and related diseases or disorders. In certain embodiments, the Sigma receptor is a Sigma-I receptor (also known as Sigma I).
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
An angle-adjustable ratchet tool comprises a body comprising a handle portion, comprising a connection to an energy source, and a switch connected to the energy source, a motor housing portion rotatably attached to the handle portion at a hinge point, the motor housing portion comprising a motor connected to the energy source, and a head mechanically connected to the motor and having a tip, the tip oriented to rotate about an axis orthogonal to an axis of rotation of the motor, wherein the switch is configured to provide energy to the motor from the energy source when the switch is pressed, and wherein the motor housing portion is configured to rotate at the hinge point with respect to the handle portion at a total angle of travel of at least ±20°.
A device for engaging a zipper is described. The device includes a cuff having a substantially flat central region with two opposing ends curved towards each other, thereby defining a cuff inner surface and an outer surface, and at least one extension extending outwardly from the outer surface of the cuff. Also described are methods of engaging or disengaging a zipper mechanism using the devices described herein.
In one aspect, the present invention relates to a method of identifying an infertile or a hypofertile subject, wherein the method comprises comparing the sperm TFAM level from the spermatozoa of the subject with that of a reference TFAM level, wherein the lower level TFAM from the spermatozoa of the subject relative to the reference indicates that the subject is infertile or hypofertile.
A61K 35/52 - SpermProstateSeminal fluidLeydig cells of testes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
The invention provides an ectromelia virus vector for expression of heterologous sequences under the control of a viral early/late promoter, and methods of use thereof for immunotherapy, cancer treatment and treatment of infectious disease.
A hemp-based nonwoven material manufactured by an air bonding process comprising a temperature of 150° C. for two minutes; said nonwoven material comprising between 1% and 99% hemp and between 1% and 99% of at least a second fiber; wherein the at least a second fiber is a synthetic fiber having a melt temperature of above 150° C.
The invention relates to chemical compounds containing 5-membered heterocyclic non-saturated rings and derivatives thereof and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.
C07C 233/33 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
C07C 15/14 - Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
Disclosed herein are compounds of the formulas: (I) as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions of these compounds. In some aspects, the compounds and compositions provided herein may be used to degrade Mdm2. Also provided are methods of administering compounds and compositions provided herein to a patient in need thereof, for example, for the treatment of cancers.
C07D 217/06 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A zero-refrigerant cooling device comprises a device body having an inlet and an outlet, a thermoelectric cooling section positioned at the inlet of the device body comprising at least one thermoelectric cooling module, the thermoelectric cooling module having a hot side and a cold side, the thermoelectric cooling section further comprising a cooling chamber section in which the cold side of the at least one thermoelectric cooling module is positioned, a fan configured to drive air from the cooling chamber section toward the outlet of the device body, and a humidifying section positioned between the fan and the outlet of the device body, the humidifying section comprising an evaporative pad. A method of cooling air is also disclosed.
This invention relates to a method for detecting shed or circulating tumor cells in a biological fluid using labeled pituitary adenylate cyclase activating peptide or vasoactive intestinal peptide.
The present disclosure provides immunogenic compositions useful for inducing immunity to polysaccharide antigens and/or and polysaccharide-containing antigens. Also included are methods of stimulating an immune response in subjects in need thereof and methods of treating, ameliorating, and/or preventing diseases and/or disorders in subjects comprising administering the immunogenic compositions of the disclosure.
A method of reducing the severity of radiation induced fibrosis (RIF) by administering to a patient at least a first dose of an MeK inhibitor such as trametinib between 0.01 mg to 2.0 mg, and after said radiation procedure, administering to said patient a further dose of the MeK inhibitor between 0.01 mg and 2.0 mg after the radiation procedure.
A device having a biocompatible polymer as a body and regularly spaced radiation seeds and regularly spaced magnetic materials disposed of within the body of the biocompatible polymer, or uniformly distributed liquid radiation and magnetic fluid materials within a polymer slab, hollow thick wall polymer shell, or thin wall polymer balloon, as suitable for surgical placement within a resection cavity for treatment of at-risk tissue in the tumor margin with local hyperthermia in combination with radiation and potentially also with chemotherapy and/or immunotherapy that is slowly released from the biocompatible polymer.
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
The β2-adrenergic receptor (β2AR) is a primary target in the treatment of airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Since β-agonist treatment of airway disease can have severe side effects, compounds that attenuate the side effects of β-agonists have been identified via their ability to inhibit β2AR interaction with β-arrestins. These compounds are specific for the β2AR and effectively protect against the desensitization observed with β-agonist treatment in model cells and airway tissue. The present disclosure provides compounds and methods for treating airway disease, such as but not limited to COPD and/or asthma.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
43.
BETA-2 ADRENORECEPTOR MODULATORS AND METHODS OF USING SAME
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A hemp hurd-based nonwoven material comprising a portion of hemp hurd and a portion of at least one other material; wherein the material is a natural or synthetic fiber selected from the group consisting of: polyester, nylon, polyethylene, polypropylene, cotton, flax, jute, ramie, bicomponent fibers, wood pulp, and other fibrous materials; and wherein the nonwoven material comprises between 1% and 99% hemp hurd.
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
D04H 1/407 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties containing absorbing substances, e.g. activated carbon
D04H 1/4382 - Stretched reticular film fibresComposite fibresMixed fibresUltrafine fibresFibres for artificial leather
D04H 1/64 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by applying, incorporating or activating chemical or thermoplastic bonding agents, e.g. adhesives the bonding agent being applied in wet state, e.g. chemical agents in dispersions or solutions
D04H 1/732 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by fluid current, e.g. air-lay
D21F 11/00 - Processes for making continuous lengths of paper, or of cardboard, or of wet web for fibreboard production, on paper-making machines
D21H 11/12 - Pulp from non-woody plants or crops, e.g. cotton, flax, straw or bagasse
A drug delivery device having; a pocket with first and second outer surface portions surrounding a closed interior volume; the first outer surface portion having a thickness greater than the second outer surface portion; and a quantity of cavitation nuclei positioned in the closed interior volume configured to rupture when exposed to acoustic pressure, breaking the second outer surface portion and releasing a quantity of a drug from the closed interior volume.
A protective sleeve device for positioning on a limb of a subject, having a sleeve having a proximal end and a distal end, and configured to fit over a limb of a subject, an adjustable cuff positioned at each of the proximal and distal ends of the sleeve; and an adhesive ridge, wherein the adhesive ridge is configured to prevent the proximal cuff from sliding distally down the subject's limb when the adhesive ridge is positioned on the subject's limb under the sleeve and distal to the proximal cuff.
A method of generating a quantitative characterization of injury presence and status of spinal cord tissue using an adaptive CNN system for use in diagnostic assessment, surgical planning, and therapeutic strategy comprises preprocessing for artifact correction of diffusion based, spinal cord MM data, training an adaptive CNN system with healthy and abnormal (injured/pathologic) spinal cord images obtained by imaging a population of healthy, typically developed spinal cord subjects and subjects with spinal cord injury, evaluating a novel, diffusion-based MM image for injury biomarkers using the adaptive CNN system, generating a three-dimensional predictive axonal damage map for quantitative characterization and visualization of the novel, diffusion-based MM image, and transmitting the sets of healthy and injured spinal cord images back to a central database for continued improvement of the adaptive CNN system training. A system for defining a predictive spinal axonal damage map is also described.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
48.
Persistent Luminescent Nanoparticle and Articles Comprising the Same
An article comprising a luminescent nanoparticle is described, wherein the luminescent nanoparticle is selected from the group consisting of oxide nanoparticles, aluminate nanoparticles, and germanate nanoparticles; and wherein the luminescent nanoparticle is doped with one or more metals or rare-earth elements. A method of making a luminescent nanoparticle is also described, the method comprising the steps of: providing a nanoparticle, doping the nanoparticle with one or more chemical elements, heating the nanoparticle to a temperature of between about 1000° C. and about 1200° C. to alter the crystal structure of the nanoparticle and/or to create oxygen vacancies in the nanoparticle. A persistent luminescent nanoparticle is described, said persistent luminescent nanoparticle being selected from the group consisting of: LaAlO3 nanoparticles, Gd2O3 nanoparticles, SrAl2O4 nanoparticles, Y2O3 nanoparticles, and combinations thereof; wherein the nanoparticle is doped with about 1% or less of a chemical element selected from the group consisting of: holmium, europium, ytterbium, neodymium, magnesium, and combinations thereof.
The present disclosure relates to compositions and methods for treating bladder cancer. In some embodiments the compositions and methods involve using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of bladder cancer, including metastatic breast cancer.
The invention relates to pyrrolidine and imidazolidine derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.
C07C 235/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
The present disclosure relates to Dsg2 binding molecules, nucleic acid molecules encoding the Dsg2 binding molecules and compositions comprising the same and methods of use thereof for treating or preventing cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to methods and compositions useful for treating cancer in a subject in need thereof. Said methods and compositions comprising inhibitors of toll-like receptor 4 (TLR4) signaling.
The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Aspects of the present invention relate to a mobile IV stand including a base having a top surface and a bottom surface, the base further including a central region, a front end, and a back end defined by two legs extending from the central region, at least one wheel on the bottom surface of the base underneath each leg, and at least one wheel on the bottom surface of the base underneath the central region, an IV pole extending from the top surface of the base, and a handle pole extending from the top surface of the base, wherein the handle pole is separate and independent from the IV pole, and wherein the handle pole moves along at least one axis between at least a first and second lockable position.
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
A61G 12/00 - Accommodation for nursing, e.g. in hospitals, not covered by groups , e.g. trolleys for transport of medicaments or foodPrescription lists
A61H 3/04 - Wheeled walking aids for patients or disabled persons
F16M 11/42 - Stands or trestles as supports for apparatus or articles placed thereon with arrangement for propelling the support
F16M 11/10 - Means for attachment of apparatusMeans allowing adjustment of the apparatus relatively to the stand allowing pivoting around a horizontal axis
A device and a signal processing method that can monitor human memory performance by recognizing and characterizing high-gamma (65-250 Hz) and beta (14-30 Hz) band oscillations in the left Brodmann Area 40 (BA40) of the brain that correspond with the strength of memory encoding or correct recall. The signal processing method detects high-gamma and beta band oscillations in the electrical signals recorded from left BA40, and quantifies the spectral content, power, duration, onset, and offset of the oscillations. The oscillation's properties are used to classify the subject's memory performance on the basis of a comparison with the subject's prior human memory performance and the properties of the corresponding oscillations. A report of the subject's current memory performance can be utilized in a closed loop brain stimulation device that serves the purpose of enhancing human memory performance.
Type I membrane proteins heterodimers are provided. Accordingly, there is provided a heterodimer comprising two polypeptides selected from the group consisting of SIRPalpha, PD1, TIGIT, LILRB2 and SIGLEC10, wherein each of the two polypeptides is capable of binding a natural binding pair thereof, and wherein the heterodimer does not comprise an amino acid sequence of a type II membrane protein capable of binding a natural binding pair thereof. Also provided are nucleic acid constructs and systems encoding the heterodimer, host-cells expressing same and methods of use thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
57.
DEVICE FOR PERIURETHRAL BULKING AND METHODS INCORPORATING THE SAME
A device for periurethral bulking is provided. The device includes a distal end comprising a sheath member having a optically transparent tip. The sheath member is confgured to include: a distal portion of a cystoscope; and a plurality of needles, wherein each of the plurality of needles includes a respective pathway. The device also includes a proximal end comprising viewing optics of the cystoscope. The device also includes a bridge attachment positioned in between the distal end and the proximal end, wherein the bridge attachment is in fluidic communication with the plurality of needles. The optically transparent tip comprises a plurality of outlet channels which allow passage of only a single needle. Each of the plurality of outlet channels is configured to guide a respective needle to an angle of about 45-90 degrees. Each needle and the respective pathway of the plurality of needles are bendable to about 45-90 degrees.
Provided herein are methods for treating overactive bladder (OAB) and stress urinary incontinence (SUI). The method for treating OAB includes administering a therapeutically effective amount of plasma adjacent to a subject's posterior bladder wall. The method for treating SUI includes administering a therapeutically effective amount of adipose cells mixed with plasma adjacent to a subject's urethra. Also provided herein are kits for treating OAB and SUI according to the methods.
Provided herein are an upper extremity mobility assistive device and a method of restoring movement of a user's extremity. The upper extremity mobility assistive device includes a main control board; at least one input article coupled to an input of the main control board; and a least one mobility assist element coupled to an output of the main control board, where any input article can be coupled to any mobility assist element. The method includes fitting the upper extremity mobility assistive device to the user's extremity; securing the orthosis device to the user's extremity; receiving at least one input signal at the main control board of the device; and generating at least one output to move the user's extremity. Also provided herein is a method of stimulating movement of a user's extremity using the device disclosed herein.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61H 1/02 - Stretching or bending apparatus for exercising
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
60.
METHODS AND COMPOSITIONS FOR SELECTIVELY MODULATING GENE EXPRESSION IN MEGAKARYOCYTES AND PLATELETS
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 5/078 - Cells from blood or from the immune system
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
61.
METHODS AND COMPOSITIONS FOR SELECTIVELY MODULATING GENE EXPRESSION IN MEGAKARYOCYTES AND PLATELETS
A method of selectively modulating gene expression of one or more target genes in megakaryocytes, circulating platelets, and/or platelets generated by the transfected megakaryocytes, in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of composition comprising naked RNA oligonucleotides.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 5/078 - Cells from blood or from the immune system
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
62.
COMPOSITIONS AND METHODS OF USING TRANSFER RNAS (tRNAS)
The present invention includes a method for analyzing tRNA fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of tRNA fragments. The invention further includes diagnosing, identifying or monitoring a disease or condition, a panel of engineered oligonucleotides, a kit for a high-throughput assay, and a method and system for identifying tRNA fragments.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
63.
4'-ALKYNE-2'-DEOXYCYTIDINE-BASED COMPOUNDS AND ANTI-CANCER USES THEREOF
This invention relates, in part, to 4'-alkyne-2'-deoxycytidine-based compounds and derivatives and pharmaceutical compositions thereof for preventing or treating cancers.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
The present invention provides fragments of tRNA molecules and methods of use thereof to modulate toll like receptor (TLR) signaling, for immunotherapy and for other therapeutic applications.
Disclosed herein are methods of preparing an RNA sample for sequencing. In certain embodiments, the method includes contacting an RNA molecule in the sample with an RNA- dependent RNA polymerase (RdRp) such that the RdRp extends the RNA molecule from the 3' end of the RNA molecule using the RNA molecule as a template. Also disclosed herein are kits for preparing an RNA sample for sequencing according to certain methods, as well as methods of sequencing RNA molecules using the prepared sample. Also disclosed herein are methods of preparing an RNA molecule with a modified base. In certain embodiments, the method includes ligating a left-arm RNA segment, a middle RNA segment including the modified base, and a right-arm RNA segment in the presence of a DNA splint and DNA disruptors.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
Adjustable vehicular safety seats are described herein. In one aspect, a child vehicular safety seat can include a seat back adapted and configured to support a child's back; and a pommel extending substantially perpendicular from adjacent to the seat back, such that the child's perineum is supported by the pommel while the child's legs hang on either side of the pommel. In one embodiment, the pommel is fixedly attached to the seat back. In another embodiment, the child vehicular safety seat can further include a pair of adjustable supports, one on each side of the pommel. In some cases, the pair of adjustable supports are movable substantially parallel to an axis defined by the pommel. In some cases, the pair of adjustable supports are movable independently. In some cases, the pair of adjustable supports are movable in tandem.
Medical port protection adapters are described herein. In one aspect, a contamination guard can include a proximal collar adapted and configured to engage with a medical port; an elastomeric medial region coupled to the proximal collar; and a distal collar coupled to the proximal collar by the elastomeric medial region; where the elastomeric medial region is adapted and configured to: bias the distal collar to extend at least partially over a distal end of the port when in an unloaded position; and allow the distal collar to resiliently travel proximally when loaded to permit engagement with the distal end of the medical port.
One aspect of the invention provides a processor-implemented method for conducting a remote neuro-ophthalmic examination using a mobile device. The method includes: receiving, from a distance sensor of a remote device, data corresponding to a distance of a user from the mobile device, determining, from the received data, a distance of the user from the mobile device, adjusting a size parameter of a neuro-ophthalmic examination of the mobile device; and displaying the neuro-ophthalmic examination via a display of the mobile device and according to the size parameter.
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/18 - Arrangement of plural eye-testing or -examining apparatus
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
H04M 1/72403 - User interfaces specially adapted for cordless or mobile telephones with means for local support of applications that increase the functionality
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
70.
TARGETING NEUROPOD CELL GUCY2C TO CONTROL VISCERAL PAIN AND APPETITE
The use of GUCY2C agonists in combination with PDE3 inhibitors in methods of treating the individual who has been identified as experiencing chronic visceral pain or in methods of suppressing appetite are disclosed. Compositions or kits comprising GUCY2C agonists and PDE3 inhibitors for use in methods of treating of an individual who has been identified as experiencing chronic visceral pain or in methods of suppressing appetite are disclosed.
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
71.
Systems-level Analysis of 32 TCGA Cancers Reveals Disease-Dependent tRNA Fragmentation Patterns and Very Selective Associations with Messenger RNAs and Repeat Elements
Methods of treating a disease by leveraging positive and negative correlations between tRNA-derived fragments (tRF) and messenger RNA (mRNA) wherein said correlations can be used to establish a level of granularity that is specific to a disease of interest wherein said disease-specific positive and negative correlations can allow a level of therapeutic intervention that will be unprecedented because it will have been informed by three dimensions: at least one mRNA of interest; at least one tRF that are positively/negatively correlated with it; and, the identity of the disease in which one wishes to modulate the abundance of the at least one mRNA of interest.
Systems and methods for blind spot tracking are described herein. In one aspect, a computer-implemented method can include generating a repositionable animated object on a display screen; receiving input from the user of the display screen when the repositionable animated object transitions from within a viewing range of the user to outside of the viewing range; determining a position of the repositionable animated object on the display screen based on a timing of the received input; and determining a distance away from the display screen for the user based on the position of the repositionable animated object.
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
73.
SYSTEMS AND METHODS FOR MOTOR FUNCTION FACILITATION
Systems and methods for motor function facilitation are described herein. In one aspect, a computer-implemented method for assisted actuation of a patient movement can include: receiving a set of neural signals from a set of neural sensors; extracting a set of features from the set of neural signals; inputting the set of features into a classification model; determining from the classification model an attempted activity of a user; and transmitting a set of stimulation signals to one or more output effectors according to the attempted activity and the set of neural signals.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A device and a signal processing method that can be used with a device to recognize and distinguish a physiological high-frequency oscillation (HFO) from a pathological high-frequency oscillation. The signal processing method detects a physiological HFO in the electrical brain signal one regimen of electrical or optogenetic brain stimulation can be triggered, alternatively if the method detects a pathological HFO associated with epilepsy a different regimen of electrical or optogenetic brain stimulation can be triggered. Thus, the signal processing method can be utilized in a closed loop brain stimulation device that serves the dual purpose of both enhancing memory encoding, consolidation, and recall, or improving cognition, and reducing the probability of a seizure in a patient with epilepsy.
The present invention includes a method for analyzing RNA fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of rRNA fragments. The invention also includes diagnosing, identifying or monitoring a disease or condition, and a method for identifying rRNA fragments. The invention also includes diagnosing, identifying or monitoring a glaucoma in a subject in need thereof by characterizing the identity of rRNA or tRNA fragments.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A method for specifically and efficiently quantifying the expression of targeted RNA variants with specific terminal sequences suitable to identify multiple isoforms bearing complex heterogeneity in terminal sequences by hybridizing a 5′-Dbs-adapter to the 5′-end of target RNAs, wherein the 5′-Dbs-adapter has a stem-loop structure whose protruding 5′-end base-pairs with the 5′-end of target RNAs, and wherein the loop region of 5′-Dbs-adapter contains a base-lacking spacer which will terminate reverse transcription in a subsequent step; hybridizing a 3′db-adapter to the 3′-end of target RNAs, wherein the 3′-db-adapter has a stem-loop structure whose protruding 3′-end base-pairs with the 3′-end of target RNAs; ligating both adapters with target RNAs by RN12 ligation to form a “dumbbell-like” structure; and, amplifying and quantifying the ligation product by RT-PCR.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
77.
Composition and method for muscle repair and regeneration
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
A computer-implemented method is provided herein. One aspect of the method provides a computer-implemented method including: displaying a neuro-ophthalmic examination pattern comprising a plurality of segments, wherein each of the plurality of segments is displayed at a time offset and at a discrete location of a display screen compared to other segments of the plurality of segments; receiving user input during a time period which a given segment of the plurality of segments is displayed on the display screen; and generating a neuro-ophthalmic examination reported based on the displaying the neuro-ophthalmic examination pattern and the received user input.
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
A computer-implemented method is provided herein. One aspect of the invention provides a computer-implemented method including: (a) displaying a marker at a location on a display screen; (b) repositioning the marker in different locations across the display screen; (c) receiving, from a user input mechanism, user input; (d) determining a given location of the marker when the user input is received; and (e) determining from the received input, that a user views double vision of the marker at the given location.
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
80.
SYSTEMS AND METHODS FOR GENERATING NEURO-OPHTHALMIC EXAMINATIONS
A computer-implemented method is provided herein. One aspect of the invention provides a computer-implemented method including: (a) receiving a set of neuro-ophthalmic examination results for a patient: (b) identifying, from the set of neuro-ophthalmic examination results, a set of patient characteristics; and (c) adjusting one or more parameters of subsequent electronic neuro-ophthalmic examinations based on the set of patient characteristics.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
The present invention includes a method of obtaining a biological sample from the nose, nasal cavities, nasal pharynx, oral mucosa, or saliva of a subject to be used for detection of a virus (e.g., a SARS-Co V-2 virus), and kits for performing the method.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
82.
CORONAVIRUS VACCINE COMPOSITIONS AND METHODS OF USE
Provided is a method of enhancing an antigen-induced long-lasting immune response in a host comprising administering to a host an effective amount of: (a) a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen; and (b) a Coronavirus antigen that is not expressed by the rabies virus. Also provided are related compositions, kits and vaccines.
The present disclosure provides a recombinant vector from an attenuated rabies virus comprising a nucleotide sequence encoding at least one CCHFV glycoprotein and at least one mucin like domain. The disclosure further provides a method for conditioning an immune response with said recombinant virus vector incorporated in said virus virion.
A method for detecting and quantifying of the frequency of T cells to multiple antigenic peptide epitopes comprising: measuring intracellular Ca2+ signaling in individual T cells that are labeled with Ca2+ sensitive fluorophore; wherein said T cells are placed on the glass bottom of a well-covered with antibodies or other capturing proteins specific for non-stimulatory T cells' surface receptors and wherein a peptide antigens are injected into the well and the peptide binds to MHC molecules on the T-cell surface, wherein an increase in the intracellular concentration of Ca2+ in responding T cells leads to rise in intracellular fluorescence that is detected by fluorescent microscope and wherein the response rate of said detected fluorescence can be utilized to determine the quantity of responding T cells and the efficiency of said cells.
Disclosed herein are methods for treating or preventing amyotrophic lateral sclerosis (ALS) in a subject in need thereof. The method comprises isolating RNAs from a sample obtained from the subject; characterizing the RNAs and their relative abundance in the sample to identify a signature, wherein the signature is indicative of presence or absence of ALS; and administering to the subject a treatment for ALS. Also disclosed herein are methods for diagnosis of ALS, determining the stage of ALS and predicting speed of progression of ALS, using short RNA signatures associated with diagnosis, stage or progression speed of ALS.
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A sensor module retaining device having a first portion, a second portion, and a third portion. The first portion defines an open loop that is sized and configured to contour around an outer surface of a blood vessel. The second portion is opposite the third portion and the second and third portions each extend distally away from the open loop and define an open channel therebetween. The second and third portions are contiguous with and converge inwards towards the first portion.
A method of associating a sensor with a blood vessel includes providing a sensor defining a passage therethrough and at least partially encircling the outside wall of the blood vessel with at least a portion of the sensor. The method further includes compressing the passage through the sensor until a portion of the blood vessel is flattened and mechanically coupling a pressure/force transducer to the outside wall of the blood vessel in an area of vessel wall flattening.
Described herein are compounds of Formula I and methods of using said compounds for treating, ameliorating, and/or preventing cancer. The compounds are cyanine dyes, and have increased effects in hypoglycemic environments.
Described herein are compounds of Formula I and methods of using said compounds for treating, ameliorating, and/or preventing cancer. The compounds are cyanine dyes, and have increased effects in hypoglycemic environments.
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 263/56 - BenzoxazolesHydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
An endoscopic ultrasound (EUS) anchoring system is provided. The EUS anchoring system includes a needle sheath defining a sheath lumen. The EUS anchoring system also includes an endoscopic cannula translatable within the sheath lumen and defining a cannula lumen. The EUS anchoring system also includes an anchor translatable within the cannula lumen and egressable from a distal end of the endoscopic cannula. The EUS anchoring system also includes a wire suture translatable through the cannula lumen having a distal end coupled to a middle portion of the anchor. The EUS anchoring system also includes a cinch mechanism translatable within the sheath lumen and configured to: (a) cut the wire suture; and (b) couple a proximal end of the a cut wire suture still coupled to the anchor with a cinch.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and/or dissemination. The compounds contemplated in the disclosure are useful in the prevention, treatment, and/or amelioration of virus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and/or an agent that treats, ameliorates, and/or prevents one or more virus infection symptoms and/or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma1) or Sigma-2 receptor (also known as Sigma2 or TMEM97). In certain embodiments, Sigma1 inhibitors/antagonists that cause and/or trigger ER stress and/or autophagy are useful within the methods of the disclosure.
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
The present disclosure relates, in part, to compositions and methods for the at least partial removal of histamine from a fermented liquid. In one aspect, composition of the present disclosure comprises a histamine binding domain conjugated to a solid support via a cross-linker. In certain embodiments, the histamine binding domain comprises an aptamer. In certain embodiments, the histamine binding domain comprises an anti-histamine antibody.
The present disclosure relates, in part, to compositions and methods for the at least partial removal of histamine from a fermented liquid. In one aspect, composition of the present disclosure comprises a histamine binding domain conjugated to a solid support via a cross-linker. In certain embodiments, the histamine binding domain comprises an aptamer. In certain embodiments, the histamine binding domain comprises an anti-histamine antibody.
The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and/or dissemination. The compounds contemplated in the disclosure are useful in the treatment or amelioration of virus infection, such as but not limited to coronavirus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and/or an agent that treats, ameliorates, and/or prevents one or more virus infection symptoms or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma 1) or Sigma-2 receptor (also known as Sigma2 or TMEM97).
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.
A portable toilet transfer device comprises a clip configured to engage a toilet bowl, including a first end and a second end opposite the first end, comprising an interior side portion including a proximal end, a distal end, and an interior engagement member positioned at the distal end, an exterior side portion including a proximal end, a distal end, and an exterior engagement member positioned at the distal end, and a central portion connected to the proximal end of the interior side portion and the proximal end of the exterior side portion, and a handle connected to the clip. Methods of manufacture and use are also disclosed.
The present application provides a compound of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to treat the associated diseases and conditions, such as heparin-induced thrombocytopenia and thrombosis (HITT) and vaccine-induced immune thrombotic thrombocytopenia (VITT), methods of making these compounds, and pharmaceutical compositions containing these compounds are also disclosed.
36 - Financial, insurance and real estate services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Health insurance underwriting; organizing and administering pre-paid health care plans; organizing and administering preferred provider programs in the field of health care Health care services in the nature of health maintenance organizations and preferred provider organizations
A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the α2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein is a composition for treating, preventing, and/or ameliorating melanoma in a subject in need thereof. The composition includes in certain embodiments a MEK inhibitor and a PDPK1 inhibitor. The composition includes in certain embodiments a MEK inhibitor and a P13K inhibitor. Further described herein is a method of treating or ameliorating melanoma in a subject in need thereof. The method includes in certain embodiments administering to the subject an effective amount of a composition including a MEK inhibitor and a PDPK1 inhibitor. The method includes in certain embodiments adminstering to the subject an effective amount of a composition including a MEK inhibitor and a P13K inhibitor.
